CN1562007A - 一种盐酸吡硫醇冻干组合物及其制备方法 - Google Patents
一种盐酸吡硫醇冻干组合物及其制备方法 Download PDFInfo
- Publication number
- CN1562007A CN1562007A CN 200410017640 CN200410017640A CN1562007A CN 1562007 A CN1562007 A CN 1562007A CN 200410017640 CN200410017640 CN 200410017640 CN 200410017640 A CN200410017640 A CN 200410017640A CN 1562007 A CN1562007 A CN 1562007A
- Authority
- CN
- China
- Prior art keywords
- divalvon
- freeze
- hours
- dried composition
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 title claims description 11
- 238000000034 method Methods 0.000 title description 2
- 238000004108 freeze drying Methods 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008215 water for injection Substances 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims description 18
- 238000000859 sublimation Methods 0.000 claims description 18
- 230000008022 sublimation Effects 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 10
- 229960004986 pyritinol Drugs 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 7
- 239000000654 additive Substances 0.000 abstract 1
- 238000007789 sealing Methods 0.000 abstract 1
- 238000005286 illumination Methods 0.000 description 6
- 239000012456 homogeneous solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
天数 | 性状 | 含量(%) | 有关物质(%) | 溶液澄清度与颜色 | 澄明度 |
0 | 白色块状物 | 99.58 | 0.30 | 符合规定 | 符合规定 |
10天4500LX光照 | 白色块状物 | 99.46 | 0.32 | 符合规定 | 符合规定 |
10天高温60℃ | 白色块状物 | 99.51 | 0.36 | 符合规定 | 符合规定 |
天数 | 性状 | 含量(%) | 有关物质(%) | 溶液澄清度与颜色 | 澄明度 |
0 | 白色块状物 | 99.64 | 0.38 | 符合规定 | 符合规定 |
10天4500LX光照 | 白色块状物 | 99.50 | 0.44 | 符合规定 | 符合规定 |
10天高温60℃ | 白色块状物 | 99.42 | 0.35 | 符合规定 | 符合规定 |
天数 | 性状 | 含量(%) | 有关物质(%) | 溶液澄清度与颜色 | 澄明度 |
0 | 白色块状物 | 99.28 | 0.32 | 符合规定 | 符合规定 |
10天4500LX光照 | 白色块状物 | 99.35 | 0.34 | 符合规定 | 符合规定 |
10天高温60℃ | 白色块状物 | 99.24 | 0.35 | 符合规定 | 符合规定 |
天数 | 性状 | 含量(%) | 有关物质(%) | 溶液澄清度与颜色 | 澄明度 |
0 | 白色块状物 | 99.54 | 0.34 | 符合规定 | 符合规定 |
10天4500LX光照 | 白色块状物 | 99.58 | 0.33 | 符合规定 | 符合规定 |
10天高温60℃ | 白色块状物 | 99.42 | 0.30 | 符合规定 | 符合规定 |
天数 | 性状 | 含量(%) | 有关物质(%) | 溶液澄清度与颜色 | 澄明度 |
0 | 白色块状物 | 99.15 | 0.30 | 符合规定 | 符合规定 |
10天4500LX光照 | 白色块状物 | 99.08 | 0.36 | 符合规定 | 符合规定 |
10天高温60℃ | 白色块状物 | 99.16 | 0.32 | 符合规定 | 符合规定 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410017640 CN1285335C (zh) | 2004-04-13 | 2004-04-13 | 一种盐酸吡硫醇冻干粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410017640 CN1285335C (zh) | 2004-04-13 | 2004-04-13 | 一种盐酸吡硫醇冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1562007A true CN1562007A (zh) | 2005-01-12 |
CN1285335C CN1285335C (zh) | 2006-11-22 |
Family
ID=34479076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410017640 Expired - Fee Related CN1285335C (zh) | 2004-04-13 | 2004-04-13 | 一种盐酸吡硫醇冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1285335C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101810614A (zh) * | 2010-04-15 | 2010-08-25 | 杭州康泉德医药科技有限公司 | 一种稳定的注射用盐酸吡硫醇组合物及其制剂和制备方法 |
CN101164619B (zh) * | 2006-10-20 | 2011-05-18 | 山东轩竹医药科技有限公司 | 配有专用溶媒的吡硫醇注射剂 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9382671B2 (en) | 2006-02-17 | 2016-07-05 | Andrew Ungerleider | Foamed glass composite material and a method for using the same |
-
2004
- 2004-04-13 CN CN 200410017640 patent/CN1285335C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101164619B (zh) * | 2006-10-20 | 2011-05-18 | 山东轩竹医药科技有限公司 | 配有专用溶媒的吡硫醇注射剂 |
CN101810614A (zh) * | 2010-04-15 | 2010-08-25 | 杭州康泉德医药科技有限公司 | 一种稳定的注射用盐酸吡硫醇组合物及其制剂和制备方法 |
CN101810614B (zh) * | 2010-04-15 | 2012-06-20 | 杭州康泉德投资管理有限公司 | 一种稳定的注射用盐酸吡硫醇组合物及其制剂和制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1285335C (zh) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4890732B2 (ja) | 癌治療用パクリタキセル・リポソーム組成物およびその製造方法 | |
US20200022993A1 (en) | A pharmaceutical composition comprising a sulfonylurea drug and preparation method thereof | |
TW201219375A (en) | Sodium salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide | |
CN101984968A (zh) | 抗肿瘤剂替莫唑胺的药物制剂制备方法 | |
JP2018515484A (ja) | カバジタキセル脂肪乳剤注射剤、その調製方法およびその使用 | |
CN104414983A (zh) | 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺 | |
CN101513387A (zh) | 埃索美拉唑镁注射液 | |
CN1562007A (zh) | 一种盐酸吡硫醇冻干组合物及其制备方法 | |
CN101467967B (zh) | 用于静脉和脑内注射的两元溶液型制剂 | |
JP5070670B2 (ja) | N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物の凍結乾燥製剤およびその製造方法 | |
CN101444479A (zh) | 一种拉帕替尼注射液及其制备方法 | |
CN101491495B (zh) | 丹酚酸b镁注射剂、制备方法及应用 | |
CN1493283A (zh) | 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法 | |
CN107595787A (zh) | 一种注射用福沙匹坦双葡甲胺冻干制剂的制备方法 | |
CN103768011A (zh) | 福多司坦注射剂及其制备方法 | |
CN102266298A (zh) | 一种培美曲塞二钠的药物组合物 | |
CN106176626B (zh) | L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物 | |
CN108289897B (zh) | 一种瑞马唑仑的药物组合物 | |
CN101780084A (zh) | 一种以左旋亚叶酸或其盐为主要成分的注射用组合物 | |
CN102138925B (zh) | 替加环素组合物及其制备方法 | |
CN108272755B (zh) | 一种注射用盐酸吗替麦考酚酯冻干制剂及其制备方法 | |
CN111465389A (zh) | 多西他赛共缀物的药物组合物及制备方法 | |
CN103877010A (zh) | 一种罗米地辛溶液的制备方法 | |
CN103330932B (zh) | 一种米卡芬净或其盐的药物组合物 | |
CN102716107B (zh) | 水溶性布洛芬药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG JIANFENG MEDICINE CO., LTD.; JIN SANJIU Free format text: FORMER OWNER: JIN SANJIU Effective date: 20070427 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070427 Address after: 322000 Jinhua Industrial Park, Zhejiang Co-patentee after: Jin Sanjiu Patentee after: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Address before: Hangzhou City, Zhejiang province 310003 Phoenix Road No. 68 East 1307 building A Patentee before: Jin Sanjiu |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hangzhou tiger Pharmaceutical Technology Co., Ltd. Assignor: Jin Sanjiu Contract fulfillment period: 2006.7.22 to 2012.7.21 Contract record no.: 2008330000943 Denomination of invention: Pyrithioxine hydrochloride freeze-dried composition and its preparing method Granted publication date: 20061122 License type: Exclusive license Record date: 20081010 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2006.7.22 TO 2012.7.21; CHANGE OF CONTRACT Name of requester: HANGZHOU TIGER PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20081010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090320 Address after: Post editor in industrial park of Jinhua, Zhejiang: 322000 Co-patentee after: Hangzhou tiger Pharmaceutical Technology Co., Ltd. Patentee after: Zhejiang Jianfeng Pharmaceutical Co., Ltd. Address before: Post editor in industrial park of Jinhua, Zhejiang: 322000 Co-patentee before: Jin Sanjiu Patentee before: Zhejiang Jianfeng Pharmaceutical Co., Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 322000 Jinhua Industrial Park, Zhejiang Co-patentee after: Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. Patentee after: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Address before: 322000 Jinhua Industrial Park, Zhejiang Co-patentee before: Hangzhou tiger Pharmaceutical Technology Co., Ltd. Patentee before: Zhejiang Jiafeng Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061122 Termination date: 20190413 |